...Wieslab service laboratory an exclusive license to provide diagnostic services for stomach cancer based on Procognia...
...with the option to include other countries where Procognia has not already engaged another company. Procognia...
...Switzerland and the U.K. The partners will work jointly to gain regulatory approval to market Procognia's...

...Plus kit, which combines Procognia’s array of 336 human kinases with GSK’s broad-spectrum ligand technology. Procognia Ltd....

...Procognia's GlycoScope glycoanalysis technology to develop and commercialize follow-on versions of two undisclosed marketed proteins. Procognia...
...eligible for milestones and royalties. TEVA will fund the collaboration. Further terms were not disclosed. Procognia Ltd....

...Procognia's GlycoScope glycoanalysis technology to develop and commercialize follow-on versions of two undisclosed marketed proteins. Procognia...

...Ph III OctoPlus ND 1/20/05 $23.8 Ph I/II Omrix ND 4/9/99 $20.0 Mkt (surgical sealant) Procognia...

...Procognia partner SIAL launched the Panorama Human Cancer Version 1 Protein Functional Microarray. Procognia developed the...
...and SIAL has exclusive marketing rights under a 2004 deal (see BioCentury, Nov. 15, 2004). Procognia Ltd....

...HCTL sold its equity interest in Procognia Ltd. (Maidenhead, U.K.) to Gamida, which is Procognia's principal stockholder...

...license to market Procognia's protein glycoanalysis chips and related software. Financial terms were not disclosed. Procognia Ltd....

...SIAL launched Procognia's Panorama Human p53 Protein Functional Microarray, which contains wild type human p53 and...
...deal, SIAL has exclusive rights to market Procognia's protein arrays (see BioCentury, Nov. 15, 2004). Procognia Ltd....

...The companies entered into an exclusive distribution and co-marketing agreement to combine Procognia's U-c fingerprint lectin...
...high throughput, high resolution analysis of the glycosylation of proteins. PerkinElmer Inc. (PKI), Boston, Mass. Procognia Ltd....